Scilex Makes $150M Bitcoin Investment in Datavault AI Platform
Scilex Holding Company (Nasdaq: SCLX) has announced a strategic $150 million Bitcoin investment in Datavault AI Inc. (Nasdaq: DVLT). The investment will provide Datavault with growth capital to enhance its supercomputing infrastructure and expand data exchanges.
Under the agreement, Scilex will receive up to 278,914,094 shares of Datavault common stock at an effective price of $0.5378 per share. The transaction will occur in two tranches, with 15 million shares issued at initial closing and the remainder through a pre-funded warrant pending stockholder approval.
The partnership aims to capitalize on the growing biotech data monetization market, projected to reach $30-50 billion by 2024. Scilex will gain board representation rights, with the ability to nominate two directors while maintaining 10% ownership or one director at 5-10% ownership.
Scilex Holding Company (Nasdaq: SCLX) ha annunciato un investimento strategico di $150 milioni in Bitcoin in Datavault AI Inc. (Nasdaq: DVLT). L’investimento fornirà a Datavault capitale di crescita per migliorare la sua infrastruttura di supercalcolo e ampliare gli scambi di dati.
Secondo l’accordo, Scilex riceverà fino a 278.914.094 azioni ordinarie di Datavault a un prezzo effettivo di $0,5378 per azione. La transazione avverrà in due tranche, con 15 milioni di azioni emesse al closing iniziale e il resto tramite warrant pre-finanziato in attesa dell’approvazione degli azionisti.
La partnership mira a capitalizzare sul mercato in crescita della monetizzazione dei dati biotecnologici, previsto raggiungere $30-50 miliardi entro il 2024. Scilex otterrà diritti di rappresentanza nel consiglio, con la possibilità di nominare due direttori mantenendo il 10% di proprietà o uno direttore con una quota tra 5-10%.
Scilex Holding Company (Nasdaq: SCLX) ha anunciado una inversión estratégica de $150 millones en Bitcoin en Datavault AI Inc. (Nasdaq: DVLT). La inversión proporcionará a Datavault capital de crecimiento para mejorar su infraestructura de supercómputo y ampliar los intercambios de datos.
Según el acuerdo, Scilex recibirá hasta 278,914,094 acciones ordinarias de Datavault a un precio efectivo de $0,5378 por acción. La transacción ocurrirá en dos tramos, con 15 millones de acciones emitidas en el cierre inicial y el resto mediante una garantía prefinanciada en espera de la aprobación de los accionistas.
La asociación tiene como objetivo aprovechar el mercado en crecimiento de monetización de datos biomédicos, previsto alcanzar $30-50 mil millones para 2024. Scilex obtendrá derechos de representación en el consejo, con la posibilidad de nominar a dos directores mientras mantiene el 10% de propiedad o un director con una participación del 5-10%.
Scilex Holding Company (나스닥: SCLX)가 Datavault AI Inc. (나스닥: DVLT)에 $150백만 달러 비트코인 투자를 발표했습니다. 이 투자는 Datavault에 성장 자본을 제공하여 초고성능 컴퓨팅 인프라를 개선하고 데이터 교환을 확장합니다.
계약에 따라 Scilex는 Datavault의 보통주를 278,914,094주를 주당 실질가 0.5378달러로 받습니다. 거래는 두 차례로 진행되며, 초기 종가에 1,500만 주가 발행되고 나머지는 주주 승인 대기 중 예전 행사권을 통해 발행됩니다.
이 파트너십은 생명공학 데이터 수익화 시장의 성장에 맞춰 시너지를 내는 것을 목표로 하며, 2024년까지 300억~500억 달러에 이를 것으로 예상됩니다. Scilex는 이사회에서 두 명의 이사를 지명할 수 있는 권리를 얻고, 지분 10%를 유지하는 한 두 이사를, 혹은 5-10%의 지분일 때 한 명의 이사를 임명할 수 있습니다.
Scilex Holding Company (NYSE/Nasdaq: SCLX) a annoncé un investissement stratégique de 150 millions de dollars américains en Bitcoin dans Datavault AI Inc. (NYSE/Nasdaq: DVLT). Cet investissement fournira à Datavault des capitaux de croissance pour améliorer son infrastructure de supercalculate et étendre les échanges de données.
Selon l’accord, Scilex recevra jusqu’à 278 914 094 actions ordinaires de Datavault à un prix effectif de $0,5378 par action. La transaction se déroulera en deux tranches, avec 15 millions d’actions émises lors de la clôture initiale et le reste via des warrants pré-financés en attendant l’approbation des actionnaires.
Le partenariat vise à capitaliser sur le marché croissant de la monétisation des données biotechnologiques, qui devrait atteindre $30-50 milliards d’ici 2024. Scilex obtiendra des droits de représentation au conseil, avec la possibilité de nommer deux administrateurs tout en conservant 10% de participation, ou un administrateur avec une participation comprise entre 5 et 10%.
Scilex Holding Company (Nasdaq: SCLX) hat eine strategische Bitcoin-Investition über 150 Mio. USD in Datavault AI Inc. (Nasdaq: DVLT) angekündigt. Die Investition soll Datavault Wachstums capital bereitstellen, um seine Supercomputing-Infrastruktur zu verbessern und den Datenaustausch zu erweitern.
Gemäß der Vereinbarung wird Scilex bis zu 278.914.094 Aktien von Datavault zu einem effektiven Preis von $0,5378 pro Aktie erhalten. Die Transaktion erfolgt in zwei Tranchen, wobei 15 Millionen Aktien beim ersten Closing ausgegeben werden und der Rest über eine vorkonfizierte Wandelanleihe erfolgt, bis zur Genehmigung durch die Aktionäre.
Ziel der Partnerschaft ist es, den wachsenden Markt der Monetarisierung biotechnologischer Daten zu nutzen, der voraussichtlich $30-50 Milliarden bis 2024 erreichen wird. Scilex erhält Vorstandsvertretungsrechte und kann zwei Direktoren nominieren, während es 10% Eigentum behält oder einen Direktoren bei 5-10% Eigentum ernennt.
شركة Scilex القابضة (ناسداك: SCLX) أعلنت عن استثمار استراتيجي قدره $150 مليون في البيتكوين في Datavault AI Inc. (ناسداك: DVLT). ستوفر هذه الاستثمار Datavault رأس مال للنمو لتعزيز بنية الحوسبة الفائقة وتوسيع تبادل البيانات.
وفقًا للاتفاق، ستحصل Scilex على ما يصل إلى 278,914,094 سهماً عاديًا في Datavault بسعر فعّال قدره $0.5378 للسهم. ستتم الصفقة على مرحلتين، مع إصدار 15 مليون سهم عند الإغلاق الأول والباقي من خلال وورنت pre-funded قيد موافقة المساهمين.
يهدف الشراكة إلى الاستفادة من السوق المتنامي لاستثمار بيانات التكنولوجيا الحيوية، المتوقع أن يصل إلى $30-50 مليارًا بحلول 2024. ستكتسب Scilex حقوق تمثيل في المجلس، مع القدرة على تسمية عضوين مجلس إدارة مع الحفاظ على ملكية 10% أو عضو واحد عند ملكية بين 5-10%.
Scilex 控股公司（纳斯达克：SCLX）宣布在 Datavault AI Inc.（纳斯达克：DVLT）进行 1.5亿美元比特币投资的战略举措。该投资将为 Datavault 提供增长资本，用于提升其超算基础设施并扩大数据交换。
根据协议，Scilex 将以每股实价 $0.5378 的价格，最多获得 Datavault 的 278,914,094 股普通股。交易将分两笔完成，初始收盘时发行 1500 万股，其余通过事先融资的权证在获得股东批准前进行发行。
本次合作旨在利用生物科技数据变现市场的增长潜力，该市场预计在 2024 年达到 300 亿至 500 亿美元。Scilex 将获得董事会席位权，能够提名两名董事，同时保持 10% 的所有权，或在所有权为 5-10% 时任命一名董事。
Negative
- Large $150M Bitcoin investment represents significant risk exposure to crypto volatility
- Deal completion dependent on Datavault stockholder approval for second tranche
- Substantial dilution risk for existing Datavault shareholders
Insights
Scilex’s $150M Bitcoin investment in Datavault AI represents a significant pivot into data monetization with substantial ownership stake acquired.
Scilex Holding Company’s
The strategic rationale appears focused on capturing value in the biotech data monetization market, projected to reach
What’s particularly notable is the use of Bitcoin rather than cash for this transaction, signaling Scilex’s embrace of cryptocurrency in corporate treasury operations. This represents a convergence of three distinct technology domains: biotech, blockchain, and AI. Scilex apparently aims to leverage Datavault’s blockchain and AI capabilities to create a marketplace for tokenized real-world biotech assets.
This investment connects Scilex to a broader AI market projected to reach
PALO ALTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has entered into an agreement to make a
Datavault AI’s patented platform is positioned to capture value across biotech, energy, and entertainment markets, as the global AI market is projected to reach
The strategic investment is intended to capture growth in the biotech data monetization market, which is expected to reach a market size of
Under the terms of the purchase agreement between Datavault and Scilex, Scilex is expected to receive up to an aggregate of 278,914,094 shares of Datavault common stock (at an effective purchase price of
Henry Ji, Ph.D., CEO, President and Chairman of the Board of Scilex Holding Company, said, “Datavault’s cutting-edge technologies align perfectly with the biotech sector’s need for advanced data analytics, AI-driven insights, and super computing power. This investment reflects our belief in Datavault’s ability to transform markets where trust and precision are critical. Biotech is a market we know well, and we will help guide Datavault to maximum revenue generation in our sector while Datavault expands across the global economy. With our resources and their patented technology, we see an incredible opportunity to drive real global impact together.”
For more information on Scilex Holding Company, refer to www.scilexholding.com
For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com
For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.
For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.
For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.
https://www.facebook.com/scilex.pharm
https://www.linkedin.com/company/scilex-holding-company/
About Scilex Holding Company
Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system)
In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system)
Scilex is headquartered in Palo Alto, California.
About Semnur Pharmaceuticals, Inc.
Semnur is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.
Semnur Pharmaceuticals, Inc. is headquartered in Palo Alto, California, and is a majority owned subsidiary of Scilex.
About Datavault AI Inc.
Datavault AI™ (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI’s cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The company is headquartered in Beaverton, OR.
Learn more about Datavault AI at www.dvlt.ai
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, Scilex’s proposed investment in Datavault, timing thereof and anticipated use of bitcoin proceeds as growth capital for Datavault’s expansion plans, the market size of the biotech data monetization market, Scilex’s plans to create a potential marketplace for RWA in the biotech and pharmaceutical industry, Scilex’s plans to appoint directors to the Datavault board, potential Datavault stockholder approval, future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements are based on management’s current expectations of and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the ability of Scilex and its subsidiaries to achieve the benefits of the transactions contemplated with Datavault, including future financial and operating results; risks related to the outcome of any legal proceedings that may be instituted against the parties regarding the transactions contemplated with Datavault; the risk that the transactions contemplated with Datavault disrupts current plans and operations; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Datavault and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.
Contacts:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Website: www.scilexholding.com
SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.
Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.
ELYXYB® is a registered trademark owned by Scilex Holding Company.
Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc.
All other trademarks are the property of their respective owners.
© 2025 Scilex Holding Company All Rights Reserved.
FAQ
What is the value of Scilex’s (SCLX) investment in Datavault AI?
Scilex is making a $150 million Bitcoin investment in Datavault AI to accelerate its supercomputing infrastructure and expand data exchanges.
How many Datavault shares will Scilex (SCLX) receive in the investment?
Scilex will receive up to 278,914,094 shares of Datavault common stock at an effective price of $0.5378 per share, issued in two tranches.
What board rights does Scilex (SCLX) get in Datavault after the investment?
Scilex can nominate two directors while maintaining 10% ownership, or one director with 5-10% ownership of Datavault’s common stock.
What is the market opportunity for biotech data monetization targeted by the Scilex-Datavault deal?
The biotech data monetization market is expected to reach $30-50 billion by 2024, with the broader AI market projected to reach $1.8 trillion by 2030.
How will the Datavault shares be distributed to Scilex (SCLX)?
15 million shares will be issued at initial closing, with the remainder issued as a pre-funded warrant after Datavault stockholder approval for issuance exceeding 19.99% of pre-financing shares.